Oragenics, Inc.
OGEN · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4,114 | $15,491 | $10,073 | $10,586 |
| G&A Expenses | $6,444 | $5,452 | $4,480 | $5,272 |
| SG&A Expenses | $6,444 | $5,452 | $4,480 | $5,272 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$38 | -$132 | -$87 |
| Operating Expenses | $10,559 | $20,905 | $14,421 | $15,771 |
| Operating Income | -$10,559 | -$20,905 | -$14,421 | -$15,771 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$9 | $249 | $132 | $59 |
| Pre-Tax Income | -$10,568 | -$20,656 | -$14,288 | -$15,712 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10,568 | -$20,656 | -$14,288 | -$15,712 |
| % Margin | – | – | – | – |
| EPS | -1.6 | -9.18 | -7.11 | -8.09 |
| % Growth | 82.6% | -29.1% | 12.1% | – |
| EPS Diluted | -1.6 | -9.18 | -7.11 | -8.09 |
| Weighted Avg Shares Out | 6,622 | 2,250 | 2,009 | 1,882 |
| Weighted Avg Shares Out Dil | 6,622 | 2,250 | 2,009 | 1,882 |
| Supplemental Information | – | – | – | – |
| Interest Income | $46 | $180 | $136 | $76 |
| Interest Expense | $30 | $0 | $15 | $16 |
| Depreciation & Amortization | $0 | $27 | $45 | $41 |
| EBITDA | -$10,538 | -$20,598 | -$14,229 | -$15,655 |
| % Margin | – | – | – | – |